Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Safety and Pharmacology Study of Sapacitabine to Treat Advanced Leukemias or Myelodysplastic Syndromes

This study has been completed.
Sponsor:
Information provided by:
Cyclacel Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier:
NCT00380653
First received: September 23, 2006
Last updated: October 18, 2009
Last verified: September 2006
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: June 2009
  Primary Completion Date: November 2008 (Final data collection date for primary outcome measure)